Clinical study of Lifei Prescription in the treatment of acute exacerbation of chronic obstructivepulmonary disease
中药利肺方治疗慢性阻塞性肺疾病急性加重期的临床研究

摘要

目的 实验将针对慢性阻塞性肺疾病急性加重期患者实施中药利肺方治疗，对比临床疗效。方法 2017年9月到2020年9月期间，收集邵阳市中西医结合医院呼吸内科住院部的慢性阻塞性肺疾病急性加重期患者60例，随机分为2组，中药利肺方联合西药治疗（治疗组），西药治疗（对照组）。对比治疗成果。结果 从数据可见，治疗组总疗效率为96.67%，对照组为73.33%,对比具有统计学意义（P＜0.05）。与此同时，在气血指标、肺功能指标中，治疗组治疗后较之前改善明显，且优于对照组，差异具有统计学意义。结论 采用中药利肺方治疗对于慢性阻塞性肺疾病急性加重期患者的康复治疗效果显著，可有助于改善肺功能指标，值得推广。

Abstract

Objective To compare the clinical efficacy of Traditional Chinese medicine Lifei Prescription for patients with acute exacerbation of chronic obstructive pulmonary disease.
Methods From September 2017 to September 2020, 60 patients with acute exacerbation of chronic obstructive pulmonary disease in the inpatient department of respiratory Medicine, Shaoyang Hospital of Integrated Traditional Chinese and Western Medicine were collected and randomly divided into two groups: Traditional Chinese medicine Lifei Prescription combined with Western medicine (treatment group) and western medicine treatment (control group). Compare treatment outcomes.
Results According to the data, the total efficacy rate of the treatment group was 96.67%, and that of the control group was 73.33%, the comparison was statistically significant (P < 0.05). At the same time, in the indicators of qi and blood, lung function, the treatment group improved significantly after treatment, and was better than the control group, the difference was statistically significant.
Conclusion   The treatment of Traditional Chinese medicine Lifei prescription has a significant effect on the rehabilitation of patients with acute exacerbation of chronic obstructive pulmonary disease, and can help improve the lung function index, which is worth promoting.